
Angitia Bio raises $130M in Series D round
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Mercado: Xurrent names new CEO, Sonos shares on the rise
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Amgen 2025 revenues up 10% to $36.8B
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

The Trade Desk shares 52-week low after CFO change
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Mindbody parent company agrees to merger, new funding
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Atara receives FDA rejection, future uncertain
The bad news just keeps coming for Thousand Oaks-based Atara Biotherapeutics. Nearly a year after the biotechnology company laid off 50% of its workforce after one rejection from the U.S. Food and Drug Administration, Atara received another one on Jan. 12. In this notice, Atara, a company specializing in developing transformative therapies for patients with Read More →








